World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 3 April 2012
Main ID:  EUCTR2009-015556-15-IT
Date of registration: 07/06/2010
Prospective Registration: Yes
Primary sponsor: BIOGEN IDEC LTD
Public title: A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects with Relapsing Remitting Multiple Sclerosis - ND
Scientific title: A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects with Relapsing Remitting Multiple Sclerosis - ND
Date of first enrolment: 07/06/2010
Target sample size: 1800
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-015556-15
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes Randomised: yes Open: no Single blind: yes Double blind: no Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: yes Placebo: no Other: no  
Phase: 
Countries of recruitment
Austria Denmark Finland Germany Greece Hungary Italy Netherlands
Portugal Slovenia Spain Sweden United Kingdom
Contacts
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria:
1. Have signed written informed consent 2. Have a diagnosis of relapsing remitting multiple sclerosis as defined by the revised McDonald Committee criteria (Polman 2005). 3. Must have been treated with a stable regimen of either glatiramer acetate (20 mg per day SC) or interferon β-1a (44 mcg 3 times per week) as their principal first therapy for MS for 6 to 18 months prior to randomization. 4. Have had disease activity within 12 months prior to screening while on therapy; 5. Be na?ve to natalizumab. 6. Be between the ages of 18 and 60, inclusive at the time of informed consent. 7. Have a documented EDSS score between 0.0 and 5.5, inclusive.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
1. Have a diagnosis of primary progressive, secondary progressive, or progressive relapsing MS (as defined by Lublin and Reingold, 1996). 2. Have known intolerance, contraindication to, or history of non-compliance with, the use of glatiramer acetate or interferon β-1a. 3. Have had an MS exacerbation (relapse) within 30 days prior to randomization AND/OR the patient has not stabilized from a previous relapse, in the opinion of the Investigator, prior to randomization. 4. The patient is considered by the Investigator to be immunocompromised 5. Subjects for whom MRI is contraindicated, 6. History of any clinically significant (as determined by the Investigator) major disease that would preclude participation in a clinical trial. 7. History of malignant disease, including solid tumors and hematologic malignancies (with the exception of basal cell and squamous cell carcinomas of the skin that have been completely excised and are considered cured). 8. Known history of Human Immunodeficiency Virus (HIV). 9. Positive test result for Hepatitis C virus or hepatitis B virus and/or hepatitis B core antibody 10. History of transplantation or any anti-rejection therapy. 11. History of severe allergic or anaphylactic reactions or known drug hypersensitivity. 12. A clinically significant infectious illness (within 30 days prior to screening. 13. History of PML.


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Relapsing Remitting Multiple Sclerosis
MedDRA version: 9.1 Level: LLT Classification code 10063399
Intervention(s)

Trade Name: TYSABRI
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: Natalizumab
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 300-

Trade Name: COPAXONE
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Glatiramer acetate
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 20-

Trade Name: REBIF
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Interferon beta-1a
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 44-

Trade Name: REBIF*SC 12SIR 6000000UI 22MCG
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Interferon beta-1a
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 22-

Primary Outcome(s)
Main Objective: The primary study objective is to evaluate the efficacy (clinical and MRI) of switching to natalizumab compared to receiving interferon β1-a or glatiramer acetate.
Secondary Objective: The secondary study objective is to evaluate the effect on quality of life of switching to natalizumab compared to receiving interferon β1-a or glatiramer acetate.
Primary end point(s): The primary endpoint in this study is the annualized relapse rate in subjects with relapsing remitting multiple sclerosis (RRMS).
Secondary Outcome(s)
Secondary ID(s)
2009-015556-15-FI
101MS325
Source(s) of Monetary Support
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey